-AbstractBackground/Aims：Entecavir is a synthetic nucleoside analogue, cyclopentyl guanine nucleoside,
copies/ml or 2 log lower than initial HBV DNA) rates were 82%, 91% and 91% at months 3, 6 and 9, respectively. Undetectable HBV DNA (HBV DNA < 4 log10 copies/ml) rates were 49%, 73% and 85% at months 3, 6 and 9, respectively. Two patients presented with virological breakthrough without adverse effects until month 9.
Conclusions：Entecavir showed good BR and VR from month 3 and these effects continued through the 9-month observation period. This suggests that entecavir is also a good choice for the first line treatment of chronic hepatitis B (CHB). Further studies are needed to determine the long-term efficacy and drug resistance of entecavir in Korean CHB patients. These results account for number and percent of total efficacy. ALT; alanine aminotransferase, ULN; upper limit of normal. 개월째는 30명 (91%)이었다 ( HBV DNA < 5 log 10 copies/ml or 2 log lower than initial HBV DNA 19 (83) 20 (87) 20 (87) HBV DNA < 4 log 10 copies/ml 10 (43) 16 (70) 18 (78) HBeAg loss and the appearance of HBe antibody 1 (4) 4 (17) 5 (22) Negative (10) ALT < 40 (IU/L) 6(60) 8 (80) 7(70) HBV DNA < 5 log10 copies/ml or 2 log lower than initial HBV DNA 8 (80) 10 (100) 10 (100) HBV DNA < 4 log 10 copies/ml 6(60) 8(80) 10(100) 개월째 5명 (22%)이었다 (Table 3 ). The number of primary non-responders were three(9 percent). Table 4 . Characteristics of primary non responders 료한 환자였다 (Table 4) . 
